Navigation Links
Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

THE WOODLANDS, Texas, Feb. 3 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the 2010 BIO CEO & Investor Conference in New York on Monday, February 8, 2010 at 9:30 a.m., Eastern Time. The conference is hosted by the Biotechnology Industry Organization (BIO) and will take place from February 8-9, 2010.  

About BIO CEO & Investor Conference

The BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference provides a forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry through issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, and one-on-one meetings.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.



SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
2. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
3. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
4. Lexicon Announces Completion of Public Offering of Common Stock
5. Lexicon Announces Pricing of Common Stock in Public Offering
6. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
9. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
10. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 ... tecnología para cuchillas de precisión, develó hoy ... de identidad de marca. El nuevo logo ... diseño y la ingeniería de productos con ... diferencia". ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announced it has been awarded a fixed price per sprint agile development contract ... valued at $34 million over five years, provides software engineering, infrastructure, as well ...
Breaking Medicine News(10 mins):